Skip to main content
SpringerLink
Log in

Cerebral Ischemia in Antiphospholipid Syndrome

  • Chapter
Hughes Syndrome

  • 750 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cervera R, Piette J, Font J, et al. Antiphospholipid syndrome clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients Arthritis Rheum 2002;46:1019–1027.

    Article  PubMed  Google Scholar 

  2. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GRV. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford) 2003;42:200–213.

    Article  PubMed  CAS  Google Scholar 

  3. Sun KH, Liu WT, Tsai CY, et al. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum [abstract]. Ann Rheum Dis 1992;51:707.

    PubMed  CAS  Google Scholar 

  4. Khalili A, Cooper RC. A study of immune responses to myelin and cardiolipin in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1991;8:365–372.

    Google Scholar 

  5. Oosting JD, Derksen RH, Blokzijl L, Sixma JJ, de Groot PG. Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity — studies in a thrombosis model. Thromb Haemost 1992;68:278–284.

    PubMed  CAS  Google Scholar 

  6. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum 1997;40:551–561.

    PubMed  Google Scholar 

  7. Del Papa N, Raschi ER, Catelli L, et al. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta-2-glycoprotein 1 antibodies. Am J Reprod Immunol 1997;38:212–217.

    PubMed  Google Scholar 

  8. Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003;12:539–545.

    Article  PubMed  CAS  Google Scholar 

  9. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211–2219.

    PubMed  CAS  Google Scholar 

  10. Kent M, Vogt E, Rote NS. Monoclonal antiphosatidylserine antibodies react directly with feline and murine central nervous system. J Rheumatol 1997;24:1725–1733.

    PubMed  CAS  Google Scholar 

  11. Kent MN, Alvarez FJ, Ng AK, Rote NS. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain. Exp Neurol 2000;163:173–179.

    Article  PubMed  CAS  Google Scholar 

  12. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J Clin Invest 1997;100:613–619.

    Article  PubMed  CAS  Google Scholar 

  13. Blank M, Krause I, Fridkin M, et al. Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109:797–804.

    Article  PubMed  CAS  Google Scholar 

  14. Ziporen L, Polak-Charcon S, Korczyn DA, et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol 2004;11:67–75.

    Article  PubMed  Google Scholar 

  15. Connor P, Hunt BJ. Cerebral haemostasis and antiphospholipid antibodies. Lupus 2003;12:929–934.

    Article  PubMed  CAS  Google Scholar 

  16. Brey RL, Chapman J, Levine SR, et al. Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002. Lupus 2003;12:508–513.

    Article  PubMed  CAS  Google Scholar 

  17. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in Systemic Lupus Erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299–308.

    Article  PubMed  Google Scholar 

  18. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119–124.

    Article  PubMed  CAS  Google Scholar 

  19. Coull BM, Levine SR, Brey RL. The role of antiphospholipid antibodies and stroke. Neurol Clin 1992;10:125–143.

    PubMed  CAS  Google Scholar 

  20. Sibilia J, Hercelin D, Gottenberg JE, et al. Cervico-cranial artery dissection and antiphospholipid syndrome: is there a link? Am J Med 2004;116:138–139.

    Article  PubMed  Google Scholar 

  21. Ford SE, Lillicrap DM, Brunet D, Ford PM. Thrombotic endocarditis and lupus anticoagulant, a pathogenetic possibility for idiopathic rheumatic type valvular heart disease. Arch Pathol Lab Med 1989;113:350–353.

    PubMed  CAS  Google Scholar 

  22. Khamashta MA, Cervera R, Asherson RA, et al. Association of antibodies against phospholipids with valvular heart disease in patients with systemic lupus erythematosus. Lancet 1990;335:1541–1544.

    Article  PubMed  CAS  Google Scholar 

  23. Badui E, Solorio S, Martinez E, et al. The heart in the primary antiphospholipid syndrome. Arch Med Res 1995;26:115–120.

    PubMed  CAS  Google Scholar 

  24. Nesher G, Ilany J, Rosenmann D, Abraham AS. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features and treatment. Semin Arthritis Rheum 1997;27:27–35.

    Article  PubMed  CAS  Google Scholar 

  25. Asherson RA. The catastrophic antiphospholipid syndrome. A review of the clinical features, possible pathogenesis and treatment. Lupus 1998;7(suppl 2):55–62.

    Article  Google Scholar 

  26. Olguin-Ortega L, Jara LJ, Becerra M, et al. Neurological involvement as a poor prognostic factor in catastrophic antiphospholipid syndrome: autopsy findings in 12 cases. Lupus 2003;12:93–98.

    Article  PubMed  CAS  Google Scholar 

  27. Brey RL, Hart RG, Sherman DG, Tegeler CT. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190–1196.

    PubMed  CAS  Google Scholar 

  28. Levine SR, Deegan MJ, Futrell N, Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990;40:1181–1189.

    PubMed  CAS  Google Scholar 

  29. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 1992;23:189–193.

    PubMed  CAS  Google Scholar 

  30. Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069–2073.

    Google Scholar 

  31. Heinzlef O, Abuaf N, Cohen A, et al. Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol 2001;248:373–379.

    Article  PubMed  CAS  Google Scholar 

  32. Antiphospholipid Antibody in Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology 1997;48:91–94.

    Google Scholar 

  33. Toschi V, Motta A, Castelli C, Paracchini ML, Zerbi D, Gibelli A. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759–1764.

    PubMed  CAS  Google Scholar 

  34. Tuhrim S, Rand JH, Wu X, et al. Elevated anticardiolipin antibody titer is an independent risk factor for stroke in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561–1565.

    PubMed  CAS  Google Scholar 

  35. Tuhrim S, Rand JH, Wu X, et al. Antiphosphatidyl serine antibodies are independently associated with ischemic stroke. Neurology 1999;53:1523–1527.

    PubMed  CAS  Google Scholar 

  36. Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke 2001;2:1701–1706.

    Google Scholar 

  37. Singh K, Gaiha M, Shome DK, Gupta VK, Anuradha S. The association of antiphospholipid antibodies with ischemic stroke and myocardial infarction in young and their correlation: a preliminary study. J Assoc Physicians India 2001;49:537–529.

    Google Scholar 

  38. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke 2002;33:2396–2400.

    Article  PubMed  CAS  Google Scholar 

  39. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997–1002.

    PubMed  CAS  Google Scholar 

  40. Muir KW, Squire IB, Alwan W, Lees KR. Anticardiolipin antibodies in an unselected stroke population. Lancet 1994;344:452–456.

    Article  PubMed  CAS  Google Scholar 

  41. Metz LM, Edworthy S, Mydlarski R, Fritzler MJ. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci 1998;25:64–69.

    PubMed  CAS  Google Scholar 

  42. Zielinska J, Ryglewicz D, Wierzchoska E, Lechowicz W, Hier DB, Czlonkiwska A. Anticardiolipin antibodies are an indepdendent risk factor for ischemic stroke. Neurol Res 1999;21:653–657.

    PubMed  CAS  Google Scholar 

  43. Tanne D, D’Olhaberriague L, Schultz LR, Salowich_Palm L, Sawaya KL, Levine SR. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999;52:1368–1373.

    PubMed  CAS  Google Scholar 

  44. Ahmed E, Stegmayr B, Trifunovid J, et al. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Västerbotten cohort project. Stroke 2000;31:1289.

    PubMed  CAS  Google Scholar 

  45. Blohorn A, Guegan-Massardier E, Triquenot A, et al. Antiphospholipid antibodies in the acute phase of cerebral ischemia in young adults: a descriptive study of 139 patients. Cerebrovasc Dis 2002;13:156–162.

    Article  PubMed  CAS  Google Scholar 

  46. Tanne D, D’Olhaberriague L, Trivedi AM, Salowich-Palm L, Schyltz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002;21:93–99.

    Article  PubMed  Google Scholar 

  47. Wilson A, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrom. Artheritis Rheum 1999;42:1309–1311.

    Article  CAS  Google Scholar 

  48. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in Systemic Lupus Erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999;78:167–175.

    Article  PubMed  CAS  Google Scholar 

  49. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian registry. Am J Med 1996;100:530–536.

    Article  PubMed  CAS  Google Scholar 

  50. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 2004;291:576–584.

    Article  PubMed  CAS  Google Scholar 

  51. Sletnes KE, Smith P, Abdolnoor M, Arnosen H, Wisloff F. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-harmorrhagic stroke. Lancet 1992;339:451–453.

    Article  PubMed  CAS  Google Scholar 

  52. Wu R, Nityanand S, Berlund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Aterioscler Thromb Vasc Bio 1997;17:3159–3163.

    CAS  Google Scholar 

  53. Deschiens MA, Conrad J, Horellou MH, et al. Coagulations studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis. Stroke 1996;27:1724–1730.

    PubMed  CAS  Google Scholar 

  54. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Neurology 1997;28:2363–2369.

    CAS  Google Scholar 

  55. Coull BM, Goodnight, SH. Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 1990;21:1370–1374.

    PubMed  CAS  Google Scholar 

  56. Mikdashi JA, Kay GG. Neurocognitive deficits in Antiphopholipid syndrome [abstract]. Neurology 1996;46:A359.

    Google Scholar 

  57. Van Horn G, Arnett FC, Dimachkie MM. Reversible dementia and chorea in a young woman with the lupus anticoagulant. Neurology 1996;46:1566–1603.

    Google Scholar 

  58. Klemp P, Cooper RC, Strauss FJ, et al. Anticardiolipin antibodies in ischemic heart disease. Clin Exp Immunol 1988;89:411–419.

    Google Scholar 

  59. Denburg SD, Carbotte, RM, Ginsberg, JS, Denburg, J. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Intern Neuropsychol Soc 1997;3:377–386.

    CAS  Google Scholar 

  60. Hanly JG, Hong C, Smith S, Fisk JD. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999;42:728–734.

    Article  PubMed  CAS  Google Scholar 

  61. Long AA, Denburg SD, Carbotte RM, Singal DP, Denburg JA. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis 1990;49:249–253.

    Article  PubMed  CAS  Google Scholar 

  62. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999;42:735–741.

    Article  PubMed  CAS  Google Scholar 

  63. McLaurin EY, Holliday SL, Williams P, Brey RL. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 2004. In press.

    Google Scholar 

  64. Denburg SD, Carbotte, RM, Denburg, JA. Cognition and mood in systemic lupus erythematosus. Ann N Y Acad Sci 1997;823:45–59.

    Google Scholar 

  65. Lezak MD. Neuropsychological assessment, 3rd ed. New York: Oxford University Press; 1998:18.

    Google Scholar 

  66. Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms, and commentary. New York: Oxford University Press; Chap. 8.

    Google Scholar 

  67. Schmidt R, Auer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke 1995;26:749–754.

    PubMed  CAS  Google Scholar 

  68. de Moerloose P, Boehlen F, Reber G. Prevalence of anticardiolipin and antinuclear antibodies in an elderly hospitalized population and mortality after a 6-year follow-up. Age Ageing 1997;26:319–320.

    PubMed  Google Scholar 

  69. Cesbron J-Y, Amouyel Ph, Masy E. Anticardiolipin antibodies and physical disability in the elderly. Ann Intern Med 1997;126:1003.

    PubMed  CAS  Google Scholar 

  70. Chapman J, Abu-Katash M, Inzelberg R, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci 2002;203–204:81–84.

    Article  PubMed  Google Scholar 

  71. Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology 1990;40:464–467.

    PubMed  CAS  Google Scholar 

  72. Zelger B, Sepp N, Stockhammer G, et al. Sneddon’s syndrome: a long term follow-up of 21 patients. Arch Dermatol 1993;129:437–444.

    Article  PubMed  CAS  Google Scholar 

  73. Tourbah A, Peitte JC, Iba-Zizen MT, Lyon-Caen O, Godeau P, Frances C. The natural course of cerebral lesions in Sneddon syndrome. Arch Neurol 1997;54:53–60.

    PubMed  CAS  Google Scholar 

  74. Sneddon IB. Cerebral vascular lesions in livedo reticularis. Br J Dermatol 1965;77:180–185.

    PubMed  CAS  Google Scholar 

  75. Coull BM, Bourdette DN, Goodnight SH, Briley DP, Hart R. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 1987;18:1107–1112.

    PubMed  CAS  Google Scholar 

  76. Chinnery PF, Shaw PI, Ince PG, Jackson GH, Bishop RI. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome. J Neurol Neurosurg Psych 1997;62:300–301.

    Article  CAS  Google Scholar 

  77. Molad Y, Sidi Y, Gornish M, et al. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J Rheumatol 1992;19:556–561.

    PubMed  CAS  Google Scholar 

  78. Provenzale JM, Heinz ER, Ortel TL, Macik BG, Charles LA, Alberts MJ. Antiphospholipid antibodies in patients without systemic lupus erythematosus: neuroradiologic findings. Radiology 1994;192:531–537.

    PubMed  CAS  Google Scholar 

  79. Toubi E, Khamashta MA, Panarra A, Hughes GRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397–401.

    Article  PubMed  CAS  Google Scholar 

  80. Sailer M, Burchert W, Ehrenheim C, et al. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol 1997;244:186–193.

    Article  PubMed  CAS  Google Scholar 

  81. Hachulla E, Michon-Pasturel U, Leys D, et al. Cerebral magnetic imaging in patients with or without antiphospholipid antibodies. Lupus 1998;7:124–131.

    Article  PubMed  CAS  Google Scholar 

  82. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303–308.

    PubMed  CAS  Google Scholar 

  83. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995;332:993–997.

    Article  PubMed  CAS  Google Scholar 

  84. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003;349:1133–1138.

    Article  PubMed  CAS  Google Scholar 

  85. Ruiz-Irastorza G, Khamashta KA, Hunt BJ, Escuedero A, Cuadrado MJ, Hughes GRV. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: an analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002;162:1164–1169.

    Article  PubMed  Google Scholar 

  86. Derksen RHWM, de Groot PG, Kappelle LJ. Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. Neurology 2003;61:111–114.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA

    Debendra Pattanaik MD & Robin L. Brey MD

Authors
  1. Debendra Pattanaik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin L. Brey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Lupus Research Unit, St Thomas’ Hospital, London, UK

    M. A. Khamashta MD, FRCP, PhD (Deputy Head) (Deputy Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Pattanaik, D., Brey, R.L. (2006). Cerebral Ischemia in Antiphospholipid Syndrome. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/1-84628-009-5_6

Download citation

  • DOI: https://doi.org/10.1007/1-84628-009-5_6

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-873-2

  • Online ISBN: 978-1-84628-009-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation